aidsmap: Modelling study backs targeted, not universal, lenacapavir PrEP for pregnancy and breastfeeding
A new modelling study suggests that targeted use of the drug lenacapavir for pregnant and breastfeeding women in high-incidence African districts is more cost-effective than universal rollout. Researchers emphasize that this should complement, not replace, existing vertical HIV transmission prevention programs.
Why it matters
Optimizing HIV prevention strategies in resource-limited settings is critical for maximizing public health outcomes while managing limited financial budgets.
Targeted deployment of twice-yearly lenacapavir for pregnant and breastfeeding women without HIV in high-incidence districts in sub-Saharan Africa could substantially reduce vertical transmission at a fraction of the cost of universal rollout, according to a modelling study published in the Journal of the International AIDS Society . But the authors say lenacapavir should be seen as complementary to, not a substitute for, strengthening existing programmes to prevent vertical transmission.
The article reports on scientific findings from a peer-reviewed journal without emotive language or political framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in